Valuation: Cantargia AB

Market Cap 446M 47.06M 40.72M 37.98M 34.95M 65.95M 4.48B 66.7M 175M 2.24B 177M 173M 7.48B P/E 2026 *
-2.33x
P/E 2027 * -2.11x
Enterprise Value 446M 47.06M 40.72M 37.98M 34.95M 65.95M 4.48B 66.7M 175M 2.24B 177M 173M 7.48B EV / Sales 2026 *
425x
EV / Sales 2027 * 11.6x
Free-Float
97.06%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Cantargia AB

1 day-0.28%
1 week-3.96%
Current month-1.48%
1 month-17.89%
3 months-50.19%
6 months-67.60%
Current year-57.11%
1 week 1.74
Extreme 1.735
1.88
1 month 1.74
Extreme 1.735
2.21
Current year 1.74
Extreme 1.735
6.59
1 year 1.74
Extreme 1.735
6.59
3 years 1
Extreme 1
6.59
5 years 1
Extreme 1
27.92
10 years 1
Extreme 1
71.8
Manager TitleAgeSince
Chief Executive Officer 60 2025-08-31
Director of Finance/CFO 56 2023-06-14
Chief Tech/Sci/R&D Officer - 2025-10-01
Director TitleAgeSince
Chairman 66 2015-12-31
Director/Board Member 55 2017-12-31
Director/Board Member 66 2020-09-30
Date Insider Type Main position Quantity % Market Cap.
6/22/26 Buy

Chief Technology Officer

18,238 0.0073%
6/22/26 Fiscal year

Director

-74,997 0.0302%
9/2/25 Free

Chief Executive Officer

1,000,000 0.4022%
Change 5-day change 1-year change 3-year change Capi.($)
-0.28%-3.96%-43.11%-64.00% 46.89M
+4.35%+19.90%+60.59%+95.21% 62.53B
+2.83%-3.03%+27.40%+67.25% 52.43B
+0.91%-0.29%-16.22%-13.43% 23.1B
+0.27%-4.91%-10.99%+350.30% 21.4B
+0.40%+5.29%+30.11%-9.63% 21.17B
+0.75%-0.84%+33.80%-25.25% 17.76B
+9.88%+19.73%+229.67%+385.49% 15.47B
+2.08%-3.28%+21.67%+564.59% 14.68B
+1.25%+0.34%+54.03%+179.72% 14.08B
Average +2.24%+2.92%+38.70%+153.03% 24.27B
Weighted average by Cap. +2.76%+4.59%+43.19%+135.13%

Financials

2026 *2027 *
Net sales 1.05M 111K 95.81K 89.36K 82.24K 155K 10.53M 157K 412K 5.27M 416K 407K 17.6M 38.35M 4.04M 3.5M 3.26M 3M 5.67M 385M 5.73M 15.04M 193M 15.19M 14.85M 643M
Net income -179M -18.9M -16.36M -15.26M -14.04M -26.49M -1.8B -26.79M -70.29M -900M -70.99M -69.42M -3B -180M -18.95M -16.39M -15.29M -14.07M -26.55M -1.8B -26.85M -70.44M -902M -71.15M -69.58M -3.01B
Net Debt - -
Logo Cantargia AB
Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
Employees
22
Date Price Change Volume
26-08-05 SEK 1.795 -0.28% 563,655
26-08-04 SEK 1.800 +1.81% 595,204
26-08-03 SEK 1.768 -2.96% 692,793
26-07-31 SEK 1.822 +0.33% 656,466
26-07-30 SEK 1.816 -1.84% 379,185
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.795SEK
Average target price
10.00SEK
Spread / Average Target
+457.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CANTA Stock